Skip to content

Terri D’arrigo

7 papers in the library · 1 citation · publishing 2022-2024

Papers

Sort Most recent Most cited

Calls to Poison Centers Involving Psilocybin Rising in Youth

Psychiatric News May 10, 2024 Terri D’arrigo

Back to table of contents Next article Clinical & ResearchFull AccessCalls to Poison Centers Involving Psilocybin Rising in YouthTerri D'ArrigoTerri D'ArrigoPublished Online:10 May 2024https://doi.org/10.1176/appi.pn.2024.06.6.2AbstractDecriminalization, legalization of psilocybin likely play roles in both increased exposure and poisoning.Getty Images/iStock/YarphotoSince 2019, calls to U.S....

MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More

Psychiatric News April 23, 2024 Terri D’arrigo

announced in April that the Food and Drug Administration (FDA) approved the antipsychotic Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone has been approved for the acute treatment of schizophrenia since 2009. The approval was based on a phase 3 clinical trial of 414 adults with a history of bipolar I disorder....

MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide

Psychiatric News March 26, 2024 Terri D’arrigo

Back to table of contents Previous article Next article Med CheckFull AccessMedCheck; Psilocybin, Roluperidone, Latozinemab, LacosamideTerri D'ArrigoTerri D'ArrigoPublished Online:26 Mar 2024https://doi.org/10.1176/appi.pn.2024.04.4.1Psilocybin Promising for Anxiety DisorderIncannex's investigational psilocybin product PSX-001 appeared to be effective in relieving symptoms of generalized...

Med Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and Lumryz

Psychiatric News July 27, 2023 Terri D’arrigo 1 citation

Back to table of contents Previous article Next article Med CheckFull AccessMed Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and LumryzTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:27 Jul 2023https://doi.org/10.1176/appi.pn.2023.08.8.3FDA Expedites Review of Anti-Amyloid Beta Vaccine for Alzheimer’s DiseaseThe Food and Drug...

Experts Offer Tips on Talking With Patients About Psychedelics

Psychiatric News June 28, 2023 Terri D’arrigo

Back to table of contents Previous article Next article Annual MeetingFull AccessExperts Offer Tips on Talking With Patients About PsychedelicsTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:28 Jun 2023https://doi.org/10.1176/appi.pn.2023.07.7.51AbstractPsychedelics differ from one another in their mechanism of action and potential effects on the body and mind....

DOI: 10.1176/appi.pn.2023.07.7.51 (opens in new tab) MDMA Counterculture Psychoanalysis Psychotherapist +2

Experts to Discuss the Ethics of Psychedelics

Psychiatric News March 27, 2023 Terri D’arrigo

Back to table of contents Previous article Next article Annual MeetingFull AccessExperts to Discuss the Ethics of PsychedelicsTerri D'ArrigoTerri D'ArrigoPublished Online:27 Mar 2023https://doi.org/10.1176/appi.pn.2023.04.3.10AbstractA session at APA's Annual Meeting will cover the current state of psychedelics research and offer points to consider in the event of broad psychedelics...

DOI: 10.1176/appi.pn.2023.04.3.10 (opens in new tab) Psilocybin Conversation Legalization Psychotherapist +3

Med Check: Psilocybin for OCD, Nuplazid Vote, and More

Psychiatric News August 1, 2022 Terri D’arrigo

AD109 Fast Tracked for Obstructive Sleep ApneaThe U. S. Food and Drug Administration (FDA) has given fast track status to AD109, an investigational oral medication for the treatment of obstructive sleep apnea, Apnimed announced in June. The FDA fast track is a process designed to facilitate the development of drugs that treat serious conditions and fill an unmet medical need and to expedite...

DOI: 10.1176/appi.pn.2022.08.8.2 (opens in new tab) Psilocybin Placebo Atomoxetine Obstructive sleep apnea +2